Literature DB >> 29207197

Prohibitin-2 negatively regulates AKT2 expression to promote prostate cancer cell migration.

Yongmei Shen1, Yu Gao1, Hui Yuan1, Jiasong Cao1, Bona Jia1, Mingming Li1, Yanfei Peng2, Xiaoling Du1, Ju Zhang1, Jiandang Shi1.   

Abstract

Prostate cancer (PCa) is a leading cause of cancer‑associated mortality in men; however, the factors that contribute to disease development have yet to be fully elucidated. Previous studies have suggested that prohibitin-2 (PHB2), which is a multifunctional protein that contributes to various cellular processes, is positively correlated with malignant progression of PCa; however, the molecular mechanisms underlying the effects of PHB2 on the enhancement of cell migration have not been identified. The present study induced overexpression and knockdown of PHB2 in PCa cell lines (PC3 and DU145) with the aim of examining the effects of PHB2 on PCa cell migration via wound healing assays. The results indicated that PHB2 overexpression promoted migration of both cell lines. AKT serine/threonine kinase 2 (AKT2), which interacts with PHB2, has been reported to participate in cell migration; therefore, the present study examined the effects PHB2 overexpression and knockdown on AKT2 in PCa cells. The present study demonstrated that overexpression of PHB2 reduced the expression of AKT2, whereas PHB2 knockdown increased AKT2 expression in both PCa cell lines. In addition, knockdown of PHB2 enhanced the protein stability of AKT2. Furthermore, AKT2 overexpression resulted in a significant decrease in migration, whereas AKT2 knockdown promoted migration of PC3 and DU145 PCa cells. The combined overexpression of PHB2 and AKT2 inhibited migration of both cell lines, thus suggesting that AKT2 overexpression abolished PHB2-induced migration. Mechanistically, the present study suggested that PHB2 may promote PCa cell migration by inhibiting the expression of AKT2. These results provide information regarding the role of PHB2 in PCa migration and malignancy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29207197     DOI: 10.3892/ijmm.2017.3307

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  8 in total

1.  PHB2 (prohibitin 2) promotes PINK1-PRKN/Parkin-dependent mitophagy by the PARL-PGAM5-PINK1 axis.

Authors:  Chaojun Yan; Longlong Gong; Li Chen; Meng Xu; Hussein Abou-Hamdan; Mingliang Tang; Laurent Désaubry; Zhiyin Song
Journal:  Autophagy       Date:  2019-06-16       Impact factor: 16.016

Review 2.  Significance of prohibitin domain family in tumorigenesis and its implication in cancer diagnosis and treatment.

Authors:  Jie Yang; Bin Li; Qing-Yu He
Journal:  Cell Death Dis       Date:  2018-05-21       Impact factor: 8.469

3.  Estrogen receptor α-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer.

Authors:  Yongmei Shen; Jiasong Cao; Zhixian Liang; Qimei Lin; Jianxi Wang; Xu Yang; Ran Zhang; Jiaojiao Zong; Xiaoling Du; Yanfei Peng; Ju Zhang; Jiandang Shi
Journal:  Cell Commun Signal       Date:  2019-05-23       Impact factor: 5.712

4.  Prohibitin 2/PHB2 in Parkin-Mediated Mitophagy: A Potential Therapeutic Target for Non-Small Cell Lung Carcinoma.

Authors:  Han Zhang; Chuntong Yin; Xin Liu; Xue Bai; Lei Wang; Honglin Xu; Jin Ju; Linyou Zhang
Journal:  Med Sci Monit       Date:  2020-04-22

5.  PHB2 promotes tumorigenesis via RACK1 in non-small cell lung cancer.

Authors:  Bin Wu; Ning Chang; Hangtian Xi; Jie Xiong; Ying Zhou; Yingtong Wu; Shuo Wu; Ning Wang; Hongyu Yi; Yun Song; Lihua Chen; Jian Zhang
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

6.  Overexpression of Prohibitin 2 Protein is Associated with Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia.

Authors:  Young Eun Lee; Ha Jin Lim; Ju Heon Park; Hye Ran Kim; Min-Gu Kang; Young Kuk Cho; Jong Hee Shin; Myung Geun Shin
Journal:  Ann Lab Med       Date:  2022-09-01       Impact factor: 4.941

7.  Biomarkers of tumor invasiveness in proteomics (Review).

Authors:  Daniel L Pouliquen; Alice Boissard; Olivier Coqueret; Catherine Guette
Journal:  Int J Oncol       Date:  2020-05-28       Impact factor: 5.650

8.  Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel.

Authors:  Giorgia Gurioli; Vincenza Conteduca; Paola Ulivi; Ugo De Giorgi; Nicole Brighi; Emanuela Scarpi; Umberto Basso; Giuseppe Fornarini; Alessandra Mosca; Maurizio Nicodemo; Giuseppe Luigi Banna; Cristian Lolli; Giuseppe Schepisi; Giorgia Ravaglia; Isabella Bondi
Journal:  BMC Med       Date:  2022-01-31       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.